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Abstract
Background: Dengue is a viral disease spread to humans by mosquitoes. Notably, there are four serotypes of
dengue viruses (DENV) that places ~40 % of the global population at risk of infection. However, lack of a suitable
drug or a preventive vaccine exacerbates the matter further. Envelope domain-III (EDIII) antigen of dengue virus
(DENV) has garnered much attention as a promising vaccine candidate for dengue, in addition to its use as a
diagnostic intermediate. Hence developing a method for efficient production of high quality recombinant EDIII is
important for research and industrial purpose.
Results: In this work, a Pichia pastoris system was optimized for the secretory over-expression of DENV serotype-3
EDIII under the control of methanol inducible AOX1 promoter. Temperature alone had a significant impact upon
the amount of secretory EDIII, with 2.5-fold increase upon reducing the induction temperature from 30 to 20 °C.
However surprisingly, supplementation of culture media with Casamino acids (CA), further augmented secretory
EDIII titer, with a concomitant drop of intracellular EDIII levels at both temperatures. Though, reduction in
intracellular retention of EDIII was more prominent at 20 °C than 30 °C. This suggests that CA supplementation facilitates
overexpressing P. pastoris cells to secrete more EDIII by reducing the proportion retained intracellularly. Moreover, a
bell-shaped correlation was observed between CA concentration and secretory EDIII titer. The maximum EDIII expression
level of 187 mg/L was achieved under shake flask conditions with induction at 20 °C in the presence of 1 % CA. The
overall increase in EDIII titer was ~9-fold compared to un-optimized conditions. Notably, mouse immune-sera, generated
using this purified EDIII antigen, efficiently neutralized the DENV.
Conclusions: The strategy described herein could enable fulfilling the mounting demand for recombinant EDIII
as well as lay direction to future studies on secretory expression of recombinant proteins in P. pastoris with
CA as a media supplement.
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Background
Dengue, a mosquito-borne disease, can be caused by
four antigenically distinct serotypes of dengue viruses
(DENVs). Recent analysis suggests that DENVs causes as
many as 390 million (95 % credible interval 284–528)
infections annually [1]. However, there is no vaccine or
drug available in the market to fight against this global
public health problem. Accumulating evidences indicate
the potential of dengue virus (DENV) Envelope Domain
III (EDIII) as a possible vaccine candidate, in addition to
its usage as a highly specific diagnostic intermediate and
a plausible target for neutralizing therapeutic antibodies
[2]. EDIII, that spans amino acid (aa) residues 297–400
of the E protein, is an immunoglobulin (Ig)-like domain.
It is implicated in the binding of the virion to the host
cell surface receptor and contains multiple type and sub-
type specific neutralizing epitopes [3]. Identity amongst
the EDIIIs of the four DENV serotypes is 60–70 %
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(Additional file 1: Figure S1), yet these domains are anti-
genically distinct and can be used for the serotyping of
immune response [2, 4]. Because of its unique fea-
tures, recombinant versions of EDIII have also found
extensive utility in basic research, for understanding
host-virus interactions, and immune response against
natural infection [2, 3].
Numerous expression systems have been reported for
the production of recombinant EDIII from different
DENV serotypes, however E. coli remains the most
widely used expression host [4–6]. Soluble expression of
EDIII in E.coli involves the fusion of protein with a large
solubility tag, such as MBP [5]. In the absence of a solu-
bility tag, overexpressed EDIII tends to be insoluble and
hence necessitates purification under denaturing condi-
tions, followed by renaturation [4, 6].
The yeast Pichia pastoris offers several advantages as a
protein production host. It harbors a strong yet tightly
regulated alcohol oxidase I (AOX1) promoter that allows
for efficient expression of recombinant protein. P. pas-
toris also allows for very high levels of extracellular
secretion of recombinant protein into culture media
with minimal secretion of endogenous proteins [7].
Use of P. pastoris for the secretory expression of
DENV serotype-2 EDIII with shake flask, achieving titer
of 2.2 mg/L, and bioreactor, achieving titer of 172 mg/L
has been reported [8]. Secretion of DENV serotype-1
EDIII in P. pastoris has also been shown but without any
information on the titer of the secreted protein [9].
Here we report the construction and optimization of a
secretory P. pastoris clone of DENV serotype-3 EDIII for
high-level secretion of EDIII into minimal media. We
show for the first time a dosing effect of CA supplemen-
tation in culture media on the secretory expression of
recombinant protein in P. pastoris. Our data clearly sug-
gest that CA supplementation increases the secretory
titer of recombinant EDIII by reducing the intracellular
retention of recombinant protein.
Methods
Reagents
Anti-penta His mAb, Ni-NTA superflow resin and Ni-
NTA His-Sorb plates were procured from Qiagen GmbH,
Germany. Anti-mouse IgG-H&L-chain-HRP-conjugate
was from JIR, USA. Acid washed glass beads (425-600
microns), HRP substrate TMB were from Sigma-Aldrich,
USA. Montanide ISA720 was from Seppic Inc., France.
BCA protein assay reagent was from Thermo Scientific,
Rockford, USA. Vero cell lines and Pan-DENV prM-
specific 2H2 mAb were obtained from ATCC, USA.
DENV EDIII-specific mAb 24A12 was generated in-
house. Alexa Fluor 488 for labeling mAbs was from Life
Technologies. N1-Europium chelate was synthesized in-
house at University of Turku, Finland. DENV-3 EDIII
gene, codon-optimized for P. pastoris expression, was ob-
tained from GeneArt AG, Germany. Casamino Acids
(Bacto casamino acids: acid-hydrolyzed casein, low so-
dium chloride and iron concentrations) Cat # 223050
from Becton, Dickinson and company, USA. CA are a
mixture of amino acids and some very small peptides (<5
amino acids) obtained from acid hydrolysis of casein.
Generation of DENV-3 EDIII expressing P. pastoris clone
The synthetic codon-optimized DENV-3 EDIII gene
(Additional file 2: Figure S2) was cloned under the con-
trol of AOX1 promoter of pPICZαA vectors (Life Tech-
nologies) and integrated into the genome of P. pastoris
MutS strain KM71H. Keeping future requirements in
mind, Muts (methanol utilizing slow) was preferentially
selected over a Mut+ (methanol utilizing plus) strain
owing to the ease of handling of the former during
large-scale production. In contrast to Mut+, methanol
accumulation does not hyper-accelerate the growth of
Muts, and hence enables better control over heat and
oxygen demand during large-scale production [10].
Transformants obtained through zeocin selection,
were screened for EDIII expression. Test tube cultures
of 30 EDIII transformants and 1 negative control
(KM71H containing empty pPICZαA) were set up in
3 ml YPD and incubated for 72 h at 30 °C with shaking
at 300 rpm, ensuing equal confluence. From these pre-
cultures, 50 μl aliquots were used to inoculate 8 ml buff-
ered glycerol-complex media (BMGY) [1 % yeast extract,
2 % peptone, 100 mM Potassium phosphate, pH 5.8;
1.34 % YNB; 4x10−5% Biotin; 1 % Glycerol] in duplicate
tubes. Cultures were allowed to shake at 300 rpm, at
30 °C for 30 h (OD600 = ~25). Cells were pelleted by low
speed centrifugation (1500× g) and re-suspended in 3 ml
buffered methanol-complex media (BMMY) [1 % yeast
extract, 2 % peptone, 100 mM Potassium phosphate,
pH 5.8; 1.34 % YNB; 4×10−5% Biotin; 2 % Methanol]. In-
ductions were maintained for 3 days at 30 °C. During
this time, 2 % (v/v) methanol was added at 24 h inter-
vals. After 3 days of induction, cultures were centrifuged
and supernatant were used for immunoassay for the
determination of EDIII secretion.
Culture condition optimization
The best secretory-clone was used for optimization exper-
iments in shake-flask setting. The growth phase was per-
formed in buffered minimal glycerol (BMG) [100 mM
Potassium phosphate, pH 5.8; 1.34 % YNB; 4×10−5% Bio-
tin; 1 % Glycerol] and induction phase in buffered min-
imal methanol (BMM) [100 mM Potassium phosphate,
pH 5.8; 1.34 % YNB; 4×10−5% Biotin; 2 % Methanol]. To
optimize culture conditions to increase the secretion level
of EDIII protein, effect of induction temperature (20 °C
and 30 °C) and CA supplementation, at different
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concentrations (0.25, 0.5, 1.0, 1.5 and 2 % w/v), in the
BMM media was investigated. A starter culture was set up
by inoculating 50 ml YPD medium with the P. pastoris
EDIII clone #27 glycerol stock and incubated for ~20 h at
30 °C with shaking at 270 rpm. This starter was used to
inoculate 1500 ml of BMG to a starting OD600 = 0.08 and
divided equally into three 2 L baffled flasks (500 ml each).
Culture was allowed to grow at 30 °C with shaking, at
270 rpm, for ~24 h (OD600 = ~30). Cells were harvested
by centrifuging at 1500×g for 5 min at RT, and washed
with sterile double-distilled water. Cells were resuspended
in water to an OD600 = 120 and 25 ml of this suspension
was added into twelve 250 ml baffled flasks prefilled with
25 ml of 2× BMM media and appropriate 2× [CA]. The
resulting cultures therefore had a starting, OD600 of 60 in
1× BMM containing different concentration of CA (0,
0.25, 0.5, 1.0, 1.5 and 2 % w/v). The initial OD at the start
of induction was reconfirmed at 60 (+/-0.5). Inductions
were allowed to proceed for 6 days at 20 °C (6 flasks with
0, 0.25, 0.5, 1.0, 1.5 and 2 % w/v CA) and at 30 °C (6 flasks
with 0, 0.25, 0.5, 1.0, 1.5 and 2 % w/v CA). Daily methanol
feed of 2 % (v/v) was added in each flask to maintain the
induction. In all the above-mentioned cases, culture sam-
ples were withdrawn at 24 h intervals, centrifuged, and
the clarified supernatants were collected and further used
for SDS-PAGE, western blot and immunoassay. Cell pel-
lets were used for extraction of total intracellular proteins.
Total intracellular protein extraction
To extract total intracellular protein, a buffer containing
strong denaturant was used. Cell pellet of 1 ml culture
was re-suspended in 200 μl of lysis buffer [6 M
Guanidine-HCl, 50 mM Dithiothreitol, 50 mM phos-
phate buffer pH 7.0]. An equal volume of glass beads
were added and cells were allowed to lyse overnight on
plate shaker (Eppendorf Mix mate) at 1500 rpm, 25 °C.
The lysed cells were centrifuged and the supernatant
containing total protein was collected.
Analytical methods
EDIII levels were determined using customized im-
munoassay as reported earlier [8] except the use of
Europium labeled anti-EDIII-MAb 24A12 instead of
anti-EDIII-MAb 3H5 coupled with secondary anti-
mouse-HRP. Each sample was assayed in duplicate wells.
A reference curve (R2 = 0.98), generated in parallel using
serially diluted (2-fold) pure DENV-3 EDIII protein
(purified as mentioned below) of known concentration
(measured using absorbance at 280 nm), was used to de-
termine the EDIII levels in crude samples. Western blot
analysis was done using anti-EDIII 24A12 mAb & goat
anti-mouse HRP as primary & secondary antibody re-
spectively. For the clone screening immunoassay, anti-
EDIII 24A12 mAb and goat anti-mouse HRP were used
as primary & secondary antibody respectively.
Large-scale expression and purification
For the large-scale cultivation and expression of EDIII,
essentially the same protocol was followed as stated pre-
viously [8], except that BMM media was supplemented
with 1 % CA and induction was performed at 20 °C. The
Ni-NTA based protein purification protocol were per-
formed as previously reported [8].
Mice immunization and seroanalysis
Animal experiments were reviewed and approved by the
International Centre for Genetic Engineering and Bio-
technology institutional animal ethics committee and
adhered to the guidelines of the Government of India. A
group of five BALB/c mice (4–6 weeks old) was immu-
nized intraperitoneally on days 0, 21 and 42 with 20 μg
purified EDIII formulated in Montanide ISA 720 adju-
vant. Mock immunizations were performed in parallel
wherein PBS replaced the antigen solution in the control
group. The neutralizing capacity of immune sera were
measured using Flow-cytometry based neutralization test
(FNT) as described earlier [11]. In the FNT assay, anti-
bodies capable of neutralizing the infectivity of DENV-3
(WHO reference strain CH53489) were measured.
Briefly, Vero cells were infected with DENV-3 strain
CH-53489 incubated with pooled serum at various dilu-
tions, and the % of cells infected with the virus were
evaluated after 24 h by staining them with Alexa 488
labeled 2H2 mAb and reading it on flow cytometer.
The serum dilution, which resulted in 50 % reduction
in the % of DENV-infected cells in comparison to the
control group, has been reported as FNT50. FNT
assay for test and mock pooled samples were per-
formed in duplicate wells.
No studies were carried out on or with materials de-
rived from human subjects.
Results and discussion
Synthetic DENV-3 EDIII gene, cloned in-frame with the
S. cerevisiae α-mating factor secretory signal under the
control of methanol inducible AOX1 promoter, was in-
tegrated into the genome of P. pastoris MutS strain using
zeocin selection strategy.
Total 30 colonies were screened in test tube setting
using customized immunoassay. One clone, #27, which
secreted the maximal level of EDIII in the culture super-
natant (Additional file 3: Figure S3), was used for all
further experiments.
This study assesses the effect of low temperature in-
duction and CA supplementation on the secretory titers
of DENV-3 EDIII in shake-flask settings. Optimization
experiments were performed in minimal media instead
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Fig. 1 Coomassie stained SDS-PAGE showing secreted EDIII. Presence of secretory EDIII was determined in the supernatant of cultures induced in
the absence (CA 0 %) or presence of different concentrations of casamino acids (CA 0.25 % to 2.0 % w/v) supplemented BMM media from day 0
to day 6 at 20 °C (a) and 30 °C (b). For both panels, similar trends were observed in two independent induction experiments (Additional file 9)
Kaushik et al. BMC Biotechnology  (2016) 16:12 Page 4 of 9
of complex media (containing yeast extract and pep-
tones) owing to the ease in purification of secreted
recombinant protein from minimal media.
The effects of low temperature induction upon protein
expression and secretion have been well studied. Higher
secretory titers of recombinant protein at lower
temperature has been associated with lower cell death
[12] and slower translation ensuring reduced ER stress
[13, 14]. In concurrence, induction at 20 °C had a signifi-
cant impact upon secreted EDIII titer in our study
(Figs. 1 and 2). In contrast to 30 °C, a distinct band cor-
responding to EDIII (~14 kDa) was observed when the
culture was induced at 20 °C (Fig. 1). The total secreted
EDIII in culture supernatant was estimated at ~54 mg/L
broth for 20 °C as against ~21 mg/L broth at 30 °C
(Fig. 2). Notably a cognate 1.3 fold higher cell mass was
also observed at 20 °C compared to 30 °C (Fig. 3), which
is consistent with earlier report [12]. However, an in-
crease in accumulation of secreted EDIII was not ob-
served over time.
There are several reports suggesting a positive effect of
media supplementation with CA on the titer of secretory
proteins in yeast system [15–21]. CA supplementation
has been associated with accumulation of secretory pro-
tein over a longer induction period [15]. Additionally,
some of these studies have also tried to link the benefi-
cial effect of CA with reduction in proteolytic activity in
culture media [15, 18, 20]. However hitherto, no report
has provided a concrete explanation for the positive
effect(s) of CA.
Further, CA is also an alternative carbon and nitrogen
source for cell growth [7]. Moreover, presence of CA in
culture media doesn’t interfere in the protein purifica-
tion methods unlike yeast extract and peptones [22].
Hence to enhance EDIII accumulation over time, we de-
cided to attempt CA supplementation. Every report until
now, barring one by Toonkool et al [15] (where two
concentrations of CA in the media were evaluated), has
used a single concentration of CA [16–21, 23]. Hence, it
was worthwhile to evaluate the effect of CA at varying
concentrations. Thus, we studied the dosing effect of CA
at five different concentrations (0.25–2 % w/v). Induction
at 20 °C in the presence of CA resulted in enhanced EDIII
secretion at all concentrations (Figs. 1a and 2a). Notably,
Fig. 2 Effect of induction temperature and casamino acids supplementation on the localization of expressed EDIII. Expression was tested at six
CA concentrations (0, 0.25, 0.5, 1.0, 1.5, 2.0 % w/v) for 6 days at 20 °C (a) and 30 °C (b). EDIII, viz. secreted (green) and intracellular (red) levels were
determined using immunoassay and value inside each bar represents EDIII titers in mg/L broth. Similar patterns were observed from culture
supernatant (secretory EDIII) and cell mass (intracellular EDIII) from two independent inductions
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EDIII secretory titers varied significantly between CA con-
centrations, with maximum EDIII accumulation (187 mg/
L broth) on the 4th day in the culture supplemented with
1 % CA (Figs. 1a and 2a). This was ~3.5 times higher than
the cognate condition without CA. Interestingly a en-
hancement, was also observed for CA supplementation at
30 °C (Figs. 1b and 2b). Surprisingly a ~7.8-fold increase
in EDIII secretory titer was observed at 30 °C upon CA
addition, bridging the titer gap observed earlier between
20 °C and 30 °C induction in the absence of CA. More-
over, a correlation plot of CA concentration and titer of
secretory EDIII was found to be bell-shaped at both tem-
peratures (Additional file 4: Figure S4). This suggests, that
unless otherwise optimized, using an arbitrary supplemen-
tation of CA will invariably have suboptimal effect upon
secretory expression of recombinant protein (Figs. 1 and
2). Notably reports suggesting negative effect of CA sup-
plementation on the accumulation of recombinant
secretory protein [23], might be due to the use of non-
optimal CA concentration for study.
A higher growth rate (~1.3 fold) (Fig. 3a and b top)
alone in the presence of CA however, cannot rationalize
the observed unprecedented increase in EDIII titer. We
could also observe a buffering effect of CA on culture
pH when induced at 20 °C (Fig. 3a, Bottom). Such an ef-
fect of CA has also been reported by others [15, 16].
But, this might not be a decisive factor for enhanced
EDIII secretion, since the pH of the culture was also
stable when induced at 30 °C in the absence of CA
(Fig. 3b, Bottom). The reduction of pH at 20 °C in the
absence of CA might be associated with the higher
growth at 20 °C compared to 30 °C (Fig. 3). We have
also observed higher growth and similar reduction in pH
at 20 °C in BMM for KM71H cells harboring gene-less
pPICZαA cassette (Additional file 5: Figure S5). CA has
been associated with reduction of proteolytic activity in
culture broth [7, 15, 18, 20]. However, this could only be
a minor factor in enhanced EDIII accumulation, as we
did not observe any significant proteolysis of EDIII in
the absence of CA (Additional file 6: Figure S6). En-
hancement in secretory EDIII titer was visible from Day
1 post induction in the presence of CA, negating a mere
stabilizing role of CA. In agreement, a significant decline
in retained (intracellular) EDIII levels was observed upon
CA supplementation in a dose-dependent manner (Fig. 2).
Western blot analysis of normalized total cell lysates cor-
roborated with this finding as EDIII was barely detected in
cells induced in the presence of CA at both 20 °C (>0.5 %
CA) and 30 °C (2 % CA) (Fig. 4). The ratio of secreted/
intracellular EDIII on the 4th day of induction was mea-
sured at 0.62 (0 % CA, 20 °C), 37.4 (1 % CA, 20 °C), 0.18
(0 % CA, 30 °C) and 4.38 (1 % CA, 30 °C). These
results clearly suggest a CA-dependent increase in
EDIII secretion, however the reduction in intracellular
Fig. 3 Effect of temperature and CA supplementation on cell growth and culture pH. Cultures induced at 20 °C (a) and 30 °C (b) were observed
for variation in growth profile (top) and pH (bottom) over time (days). Growth profile was determined by measuring the cell density for each time
point at 600 nm. Cells were harvested and pH was measured for the retrieved cell-free media. Tables containing absolute OD600 and pH values
are also provided as additional information (Additional file 8: Table S8). Similar trends were observed in two independent induction experiments
(Additional file 9)
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retention of EDIII is less prominent at 30 °C com-
pared to 20 °C.
Intracellular accumulation of protein, intended for se-
cretion, is well described and congestion of endoplasmic
reticulum (ER) folding and secretion capacity during
protein trafficking is the most common rate-limiting fac-
tor [7, 13, 24]. However interestingly, intracellularly
retained EDIII (without CA or at low CA concentra-
tions) was essentially found to be in a matured form
(processed α-prepro leader sequence) especially at 20 °C
(Fig. 4a), indicating that the protein was already proc-
essed at the Golgi apparatus (pro part of signal sequence
cleaved by Golgi resident Kex2 protease). This indicates
that ER congestion is not the main factor for intracellu-
lar EDIII retention in the absence of CA. It is possible
that CA might be modulating some other non-ER check-
points. Moreover, we cannot exclude the possibility of a
cumulative effect of multiple yet unknown mechanisms
modulated by CA supplementation.
Multiple strategies have been described to increase the
titer of secretory protein including the use of different
signal sequences, overexpression of secretion and folding
aid(s), manipulation in cell-wall biogenesis and different
cultivation techniques [7, 24]. However, no report asso-
ciating an ameliorating effect of CA supplementation on
active secretion of recombinant protein in P. pastoris ex-
ists. Though, CA supplementation has been reported to
increase the accumulation of secreted recombinant pro-
tein in culture supernatant in yeast, it have often been
linked to reduction in proteolytic activity in culture
media [7, 15, 18, 20]. Hence, our observation of a CA-
dependent increase in secretion of recombinant protein,
by reduction in intracellular retention of recombinant pro-
tein, makes this report very unique. Also, the observed
bell-shaped correlation between CA concentration and
secretory EDIII titer (Additional file 4: Figure S4) indicate
that using the right concentration of CA for supplementa-
tion is key for optimal secretion of recombinant protein.
However, deciphering a precise mechanism for the effect
will need further experiments.
Yet another feature of the devised strategy is the titer of
recombinant protein obtained (187 mg/L broth). This is
the highest reported titer for soluble EDIII, of any flavivi-
rus, without fusion with solubility enhancing tag. A ~9
fold increase in titer was achieved by supplementing with
1 % CA with reduced induction temperature. Since P. pas-
toris secretes very low amount of host-proteins, secretion
of EDIII into minimal media can be considered as the first
step of purification as can be seen from the Fig. 1. The
secretory EDIII was purified to apparent homogeneity
from culture induced at 20 °C in the presence of 1 % CA
in single step using Ni-affinity matrix (Fig. 5a). To deter-
mine the functionality of purified EDIII in terms of its
immunogenicity and ability to elicit virus-neutralizing
antibodies, mice immunizations were performed, which
resulted in very high ELISA titers of anti-EDIII antibodies
(Additional file 7: Figure S7). To determine the potential
of anti-EDIII immune sera to block the virus infectivity, a
flow cytometry based neutralization assay was performed
using Vero cells [11]. This assay revealed that the purified
recombinant EDIII elicits virus-blocking antibodies in
mice with very high neutralizing titers against DENV-3
with FNT50 value of 986 (Fig. 5b). This suggests that the
devised P. pastoris based over-expression strategy using
CA as a media supplement is an efficient system for ex-
pressing recombinant EDIII. Moreover, given the signifi-
cance of EDIII, the method described herein will be of
immense value to small diagnostic companies and re-
search laboratories that are not equipped with bioreactor
facility for the production of recombinant EDIII. The
Fig. 4 Determination of intracellularly retained EDIII. Western blot of induced P. pastoris cell lysate [day 4 harvest with different CA concentration
0.0 to 2.0 % (w/v) supplemented BMM media] to determine intracellular EDIII protein at two induction temperatures. a 20 °C induced cell lysate
showing presence of ~14 kDa EDIII protein band upto 0.5 % CA (w/v) whereas, b 30 °C induced showing gradual decrease in intracellular EDIII
protein from 0 to 1.5 % CA (w/v). Anti-EDIII 24A12 mAb & goat anti-mouse HRP were used as primary & secondary antibody respectively. N represents
negative control (KM71H cells transformed with pPICZαA) and P represents positive control (purified EDIII). Similar trends were observed with the cell
mass (intracellular EDIII) obtained from two independent inductions (Additional file 9)
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reported titer of >150 mg/L suffices ~1 million diagnostic
tests (~100–150 ng /test) from 1 L of production volume
and thus can circumvent the need for repeated culturing
and purchase.
Conclusions
In this study we have devised an efficient strategy for
enhanced secretory expression of DENV-3 EDIII in P.
pastoris. In this process we establish a novel augmenting
effect of CA upon EDIII secretion in a temperature inde-
pendent manner. We also provide evidence supporting
the need to decipher the correct concentration of CA
for supplementation for optimal secretory expression of
functional recombinant protein. To best of our know-
ledge, the titer obtained is the highest reported titer for
soluble EDIII expression without fusion with solubility
enhancing tag. The described method can find extensive
usage for the production of high quality recombinant
secretory proteins in P. pastoris in the future.
Additional files
Additional file 1: Figure S1. Multiple sequence alignment of EDIII
protein from DENV serotypes. Completely conserved residues are
highlighted in red background whereas partially conserved are boxed.
Secondary structure assignments have been made using EsPript3.0 [25]
based on PDB ID:3IRC. (PPTX 512 kb)
Additional file 2: Figure S2. P. pastoris optimized synthetic DENV 3
EDIII gene. DNA sequence (top) and encoded amino acid sequence
(bottom). (PPTX 897 kb)
Additional file 3: Figure S3. Identification of the best EDIII-expressing
P. pastoris clones. Levels of EDIII antigen in induced culture supernatants
of several clones were estimated by Immunoassay. The X- and Y-axis
indicate the clone numbers and the corresponding EDIII antigen levels in
terms of absorbance at 450 nm, respectively. Error bars represent standard
deviation of two biological replicate. Anti-EDIII 24A12 mAb & goat
anti-mouse HRP were used as primary & secondary antibody respectively.
(PPTX 736 kb)
Additional file 4: Figure S4. Effect of CA supplementation on the
secretory titer of recombinant EDIII. Total secretory EDIII titer (mg/L) for
cultures were analyzed by plotting against the concentration of CA (%)
used for induction at 20 °C (A) and 30 °C (B). A bell-shaped correlation
was observed for CA concentration with the secretory titer of recombin-
ant EDIII, advocating the importance of optimal CA concentration during
induction. Error bars represent the standard deviation calculated from
two technical replicate. (PPTX 1162 kb)
Additional file 5: Figure S5. Effect of induction temperature and CA
supplementation on cell growth and culture pH (KM71H harboring
empty vector). Cultures of P. pastoris KM71H, harboring empty pPICZαA
expression cassette, induced at 20 °C (A) and 30 °C (B) were observed for
variation in growth profile (top) and pH (bottom) over time (days).
Growth profile was determined by measuring the cell density for each
time point at 600 nm. Cells were harvested and pH was measured for the
retrieved cell-free media. (PPTX 2109 kb)
Additional file 6: Figure S6. Evaluating the proteolytic susceptibility of
secreted EDIII in culture supernatant. Proteolytic degradation for secreted
EDIII was monitored in cell-free culture supernatants to negate the bal-
ance between EDIII secretion and degradation. Culture supernatants from
P. pastoris expressing EDIII in the absence of CA, were obtained after
6 days of induction at 20° and 30 °C. Retrieved supernatants were further
incubated at their respective induction temperatures and samples were
collected at 0, 28 and 93 h interval from both. Samples were thereafter
separated on a denaturing polyacrylamide gel and visualized by Coomas-
sie stain. No visible degradation was observed indicating negligible prote-
olysis of secreted EDIII. Lane 1: Prestained protein marker; Lane 2–4: 20 °
C; Lane 5–7: 30 °C; Lane 2 & 5: 0 h; Lane 3 & 6: 28 h and Lane 4 & 7: 93 h.
(PPTX 567 kb)
Additional file 7: Figure S7. Evaluation of antibodies elicited by
recombinant DENV-3 EDIII using ELISA. Pooled sera from EDIII immunized
(solid curve) and mock (dashed curve) BALB/c mice were tested by indir-
ect ELISA using purified EDIII as coating antigen. Goat anti-mouse HRP
was used as secondary antibody. Error bars represent the standard devi-
ation calculated from two technical replicate. (PPTX 466 kb)
Fig. 5 Evaluation of Immunogenicity of purified recombinant EDIII. a Coomassie stained 15 % SDS-PAGE showing purified recombinant EDIII as
a∼ 14 kDa band in five separate elution fractions (E1 to E5) after Ni-NTA chromatography. b Determination of anti-DENV serotype-3 neutralizing
antibody titers using flow-cytometry based neutralization test. Mouse anti-EDIII pooled antisera (blue) and mock pooled antisera (red) were tested
at various dilutions (X-axis) and percent viral infection (Y-axis) was calculated. The dotted line represents 50 % infection. The error bars represent
standard deviation of two technical replicate
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Additional file 8: Table S8. Absolute values (OD600 and pH) obtained
during induction phase. (DOCX 112 kb)
Additional file 9: Data from another set of independent induction
experiment. (PDF 1054 kb)
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